Enzon says FDA approves intravenous Oncaspar for pediatric leukemia

By E. Janene Geiss

Philadelphia, Nov. 10 - Enzon Pharmaceuticals, Inc. announced Thursday that the Food and Drug Administration approved a labeling change for its pediatric oncology drug Oncaspar.

The new labeling allows the drug to be administered intravenously, a company news release said.

Intravenous administration of Oncaspar provides clinicians with an important new option that will potentially reduce the number of injections for pediatric cancer patients who require Oncaspar in their treatment regimen, officials said.

Previously, the drug's administration was limited to injection directly into the muscle, which is often painful, officials said.

Oncaspar is a PEG-enhanced version of the naturally occurring enzyme L-asparaginase and is used to treat acute lymphoblastic leukemia, mainly a childhood leukemia, officials said.

Bridgewater, N.J.-based Enzon is a biopharmaceutical company focused on development of therapeutics to treat cancer and other diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.